Photocure ASA

Earnings Release • Nov 4, 2014

Photocure: Cevira® data published in American Journal of Obstetrics & Gynecology

Photocure: Cevira® data published in American Journal of Obstetrics & Gynecology

Phase 2b results demonstrate significant and sustained efficacy in treating

human papilloma virus and precancerous lesions of the cervix

Oslo, Norway, 4 November 2014:  Photocure ASA (OSE: PHO), a specialty

pharmaceutical company focused on photodynamic technologies in dermatology and

cancer, announces the Phase 2b study of Cevira in patients with human papilloma

virus (HPV) related disease of the cervix, has been published in the prestigious

American Journal of Obstetrics and Gynecology.

Cevira, a novel and easy to use integrated drug-delivery device, demonstrated

significant and sustained efficacy in the eradication of oncogenic HPV

infections and precancerous lesions in CIN2 patients as compared to placebo.

Kjetil Hestdal, President and CEO of Photocure, said: "There is a high unmet

medical need for a therapeutic alternative for the large number of women

globally who suffer from HPV infections. The easy to use technology, high

patient and gynecologist acceptance will allow this treatment to be used widely.

The publication of this data in such an esteemed journal is testament to the

potential of Cevira as a promising new treatment option, and endorses our

ongoing partnership discussions for Cevira's development and commercialization."

Oncogenic HPV infection is the most common sexually transmitted disease causing

approx. 500,000 new cases of cervical cancer annually world-wide. CIN1 is a

mild, low-grade lesion caused by persistent oncogenic HPV infections. High-grade

lesions - CIN2, CIN3, or CIN2/3 - are more severe precancerous abnormalities

that have a higher likelihood of progressing to cancer if left untreated.

Standard treatment for CIN2/3 is surgical intervention which negatively impacts

the function of the cervix leading to an increased risk of miscarriages and

preterm births.

Professor Peter Hillemanns, Head of Department of Gynecology and Obstetrics at

the Medical University of Hannover, Germany and Principal Investigator, said:

"The increased morbidity from surgical treatment of precancerous lesions of the

cervix is well established. There is a need for well tolerated and convenient

therapeutic alternatives. Cevira is a promising product as a potential treatment

in the large group of women in need of cervix preserving treatments."

The final study results were announced in April 2013. The Phase 2b trial was

carried out in 262 patients with low to moderate grade cervical intraepithelial

neoplasia (CIN1/2) caused by oncogenic Human papilloma virus (HPV) infections.

It demonstrated a statistically significant and sustained lesion response

compared to placebo in patients with precancerous CIN2 lesions, 95% vs 62%

respectively at six months, (p<0.02). This was further supported by high

clearance of the highest risk oncogenic HPV subtypes 16 and 18 in the CIN2

cohort, of 83% vs 33% at six months. Additionally, high clearance of HPV 16 and

18 was also demonstrated in the overall CIN1/2 population, 62% vs. 33% as

compared to placebo.

The publication, "A randomized study of hexaminolevulinate photodynamic therapy

in patients with cervical intraepithelial neoplasia (CIN) 1/2" can be viewed at

http://www.sciencedirect.com/science/article/pii/S0002937814021991

For further information, please contact:

Photocure

President & CEO Kjetil Hestdal

Tel: + 47 913 19 535, Email: kh@photocure.no

CFO Erik Dahl

Tel: +47 50 55 000, Email: ed@photocure.no

Hume Brophy

Mary Clark, Hollie Vile, Supriya Mathur

Tel: +44 20 3440 5653, Email: photocure@humebrophy.com

Notes to editors

About Photocure ASA

Photocure ASA, headquartered in Oslo Norway, is a specialty pharmaceutical

company and world leader in photodynamic technology. Based on our unique

proprietary Photocure Technology(TM) platform, Photocure develops and

commercializes highly selective and effective solutions within disease areas

with high unmet medical need, such as bladder cancer, HPV and precancerous

cervical lesions, colorectal cancer and skin conditions. Our aim is to provide

solutions which can improve health outcomes for patients worldwide. Photocure is

listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is

available at www.photocure.com

About Cevira®

Cervical HPV and precancerous lesions of the cervix are highly prevalent

diseases affecting an estimated 260 million women worldwide. There is currently

no medical therapeutic treatment option available. Cevira is being developed as

the first novel therapeutic option for this large and growing patient

population. Cevira can be easily administered by gynecologists, avoiding the

potential morbidities associated with surgery.

This information is subject of the disclosure requirements acc. to §5-12 vphl

(Norwegian Securities Trading Act)

[HUG#1868277]